Successful management of a 7-year-old-female with juvenile dermatomyositis at a tertiary hospital in low-income country
Abstract
Juvenile dermatomyositis (JDM) is a rare chronic autoimmune disease belonging to idiopathic inflammatory myopathies. Pathological skin lesions and proximal weakness primarily characterize this entity, but clinical symptoms can be heterogeneous. Children are more likely to have long-term complications such as lipodystrophy, calcinosis, and vasculopathy. Calcinosis is one of the characteristic sequelae of JDM, despite recent advances in the treatment of JDM, about one-third of patients still develop dystrophic calcinosis. In low-income countries, the availability of medicines is very limited. In our case, a 7-year-old female diagnosed with JDM presented with calcinosis. Aggressive and adequate treatment with steroids, methotrexate, hydroxychloroquine, and aluminium hydroxide can treat the complications. It is challenging to establish an early diagnosis, treatment, prevention of long-term complications, and improved prognosis of JDM, which then will improve the patient’s quality of life, especially in low income countries with limited drug availability.
References
2. Swafford C, Roach ES. Juvenile Dermatomyositis and the Inflammatory Myopathies. Semin Neurol. 2020;40:342–48. DOI: https://doi.org/10.1055/s-0040-1705120
3. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16:467. DOI: https://doi.org/10.1007/s11926-014-0467-y
4. Chaudhary H, Loganathan SK, Singh S. Juvenile Dermatomyositis: Controversies and Recent Developments in Management. Indian J Rheumatol. 2020;15:S112–22. DOI: https://doi.org/10.4103/injr.injr_107_20
5. James T, Cassidy RM, Laxer RE, Carol B. Textbook of Pediatric Rheumatology. Philadelphia: Elsevier; 2011. p. 385-412.
6. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-7. DOI: https://doi.org/10.1056/NEJM197502202920807
7. Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3:e000507. DOI: https://doi.org/10.1136/rmdopen-2017-000507
8. Gupta P, Shruti S, Chaudhary V, Khullar G, Siraj F. Juvenile Dermatomyositis?: a Case Report and Review of Literature. Cureus. 2019;11:e3935. DOI: https:// doi.org/10.7759/cureus.3935
9. Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15:1–8. DOI: https://doi.org/10.1186/s12969-016-0134-0
10. Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2020;16:31–43. DOI: https://doi.org/10.1007/s12519-019-00313-8
11. Sulaiman W, Subramaniam R, Sarkan MM, Samhari AA. Overlap syndrome?: dermatomyositis and systemic lupus erythematosus with cerebral lupus and autoimmune hepatitis: a case report. Ann Arthritis Clin Rheumatol. 2021;4:1023. DOI: https://doi.org/10.25259/CSDM_112_2024
12. Twilt M, Feldman BM. An update on the diagnosis and management of juvenile dermatomyositis. Int J Clin Rheumatol. 2012;7:1-9. DOI: https://doi.org/10.2217/IJR.12.23
13. Schneider M, Murphy K. Juvenile dermatomyositis: a case study. J Pediatr Health Care. 2011;25:38–43. DOI: https://doi.org/ 10.1016/j.pedhc.2010.06.017
14. Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. Front Pediatr. 2018;6:284. DOI: https://doi.org/ 10.3389/fped.2018.00284
15. Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020;30:411–23. DOI: https://doi.org/ 10.1080/14397595.2020.1718866
16. Sawhney S, Aggarwal A. Pediatric rheumatology?: a clinical viewpoint. Singapore: Springer; 2017. p.116-118.
17. Thyoka M, Adekunle O, Pilkington C, Walters S, Arthurs OJ, Humphries P, et al. Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. Rheumatology (Oxford). 2018;57:1661–8. DOI: https://doi.org/ 10.1093/rheumatology/key144
18. Sanner H, Sjaastad I, Flatø B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford). 2014;53:1578–85. DOI: https://doi.org/ 10.1093/rheumatology/keu146
19. Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329–40. DOI: https://doi.org/ 10.1136/annrheumdis-2016-209247
20. Varnier GC, Pilkington CA, Wedderburn LR. Juvenile dermatomyositis: novel treatment approaches and outcomes. Curr Opin Rheumatol. 2018;30:650–4. DOI: https://doi.org/ 10.1097/BOR.0000000000000538
Copyright (c) 2024 Desy Wulandari, Azwin Mengindra Putera Lubis, Zahrah Hikmah, Anang Endaryanto
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2024-10-21
Published 2024-10-21
